Immugenia

Immugenia is an early-stage immuno-oncology company developing a novel CAR therapeutic approach that engineers hematopoietic stem cells to treat cancer and prevent recurrence. Its patented technology enables CARs to be selectively expressed in T cells and NK cells, leveraging their synergistic activity against cancer.